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OBJECTIVES The study evaluates the clinical course and the development of systolic and diastolic left
ventricular function in patients with chronic myocarditis with or without autoantibodies
against cardiac myosin.
BACKGROUND Patients with myocarditis often show autoantibodies against cardiac myosin. The clinical and
pathophysiologic significance of these antimyosin autoantibodies (AMAAB) is yet unknown.
The results from studies comparing the clinical course and the development of left ventricular
function in patients with chronic myocarditis with or without AMAAB are not yet available.
METHODS Thirty-three patients with biopsy proven chronic myocarditis underwent analysis of
AMAAB, right and left heart catheterization and left ventriculography at baseline and after
six months. Left ventricular volumes and ejection fraction as well as the time constant of left
ventricular relaxation “tau” and the constant of myocardial stiffness “b” were determined at
baseline and at follow-up.
RESULTS In 17 (52%) patients, AMAAB could be detected at baseline. After six months, AMAAB
were still found in 13 (76%) initially antibody-positive patients. No initially antibody-negative
(n 5 16) patient developed AMAAB during follow-up. Clinical symptoms improved slightly
in antibody-negative patients and remained stable in antibody-positive patients. Left
ventricular ejection fraction developed significantly better in antibody-negative patients
(18.9 6 10.1%) compared with antibody-positive patients (20.1 6 9.4%) (p , 0.012).
Stroke volume (SV) and stroke volume index (SVI) also improved in antibody-negative
patients (SV: 120 6 31 ml; SVI: 110 6 17 ml) compared with antibody-positive patients
(SV: 214 6 43 ml; SVI: 28 6 22 ml) (SV: p , 0.015; SVI: p , 0.016). Left ventricular
end-diastolic and end-systolic volumes and the time constant of left ventricular relaxation
“tau” did not change significantly different in antibody-positive and antibody-negative
patients. The constant of myocardial stiffness “b” improved significantly in antibody-negative
patients (26.1 6 10.8) compared with antibody-positive patients (17.3 6 22.6) (p , 0.040).
Analyzing only the persistently antibody-positive patients yielded essentially the same results.
CONCLUSIONS Antimyosin autoantibodies are associated with worse development of left ventricular systolic
function and diastolic stiffness in patients with chronic myocarditis. (J Am Coll Cardiol
2000;35:11–8) © 1999 by the American College of Cardiology
Currently, most cases of human myocarditis are thought to
be of viral origin (1–5). Viral ribonucleic acid (RNA) has
been detected in the myocardium of patients with myocar-
ditis and dilated cardiomyopathy (6–8). Although the exact
pathogenetic mechanisms are only vaguely understood, an
increasing body of evidence suggests that in the course of
myocarditis, autoimmunological mechanisms may play an
important role (9). Several autoantibodies against human
cardiac antigens have been identified in patients with
myocarditis and dilated cardiomyopathy (10–14), including
cardiac myosin (15,16). In vitro studies disclosed several
possible pathogenetic mechanisms by which autoantibod-
ies against cardiac antigens may influence cardiac func-
tion (17), but only a few clinical studies have investigated
the impact of anticardiac autoantibodies on clinical course
and functional parameters of the patients (18,19). In pa-
tients with dilated cardiomyopathy, antimyosin autoanti-
bodies (AMAAB) become undetectable in about 50% of the
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patients after one year (18). In this study, persistence of
AMAAB was associated with stable clinical conditions. To
our knowledge, no studies are available that have investi-
gated the impact of AMAAB on clinical outcome and
changes of left ventricular function in patients with myo-
carditis.
Therefore, this study investigates the association of
AMAAB with the clinical course and changes in left
ventricular systolic and diastolic function in patients with
chronic myocarditis.
METHODS
Patients. Thirty-three patients with chronic myocarditis
(20 men, 13 women, 47.4 6 12.7 years) were included in
the study. Clinical symptoms of the patients at the time of
presentation were systolic left ventricular dysfunction in 23
patients, angina pectoris in 7 patients, new rhythm distur-
bances in 6 patients and signs of congestive heart failure
with preserved systolic left ventricular function suggesting
diastolic dysfunction in 2 patients. All patients presented
initially within six months of onset of symptoms. Eleven
patients reported the presence of symptoms of upper respi-
ratory tract infections or gastrointestinal symptoms before
clinical presentation.
All patients underwent right and left heart catheterization
including left ventriculography and right ventricular endo-
myocardial biopsy. Coronary artery disease was excluded in
all patients by coronary angiography. Sera of all patients
were analyzed for the presence of AMAABs. Myocarditis
was diagnosed by histological and immunohistological anal-
ysis of endomyocardial biopsy specimen. Nineteen (58%)
patients were treated with angiotensin-converting enzyme
inhibitors, 21 (64%) patients with diuretics, 16 patients
(45%) with digitalis, 8 (24%) patients with beta-adrenergic
blocking agents, 16 (45%) patients with anticoagulants and
7 (21%) with antiarrythmic agents. No patient did receive
specific, i.e., immunosuppressive, therapy. The diagnosis of
chronic myocarditis was established in all patients by histo-
logic or immunohistologic criteria in a second endomyocar-
dial biopsy after six months, when right and left heart
catheterization, left ventriculography and assessment of
AMAAB were repeated.
Analysis of endomyocardial biopsy specimen. Endomyo-
cardial biopsies were taken transvenously via the femoral
approach from the right heart side of the interventricular
septum. The endomyocardial biopsies were examined his-
tologically according to the “Dallas Criteria” (20). The
histological sections were analyzed by light microscopy for
evidence of myocardial necrosis, interstitial fibrosis and for
the presence of lymphocytic infiltrates. Because the histo-
logical evaluation of myocardial biopsies is known to be
difficult and affected by many problems (21,22) including
high interobserver variability (23) and sampling error (24),
this technique is regarded as rather insensitive for the
diagnosis of myocarditis (25). Therefore, the biopsy speci-
mens were examined additionally with immunohistological
techniques. Monoclonal antibodies directed against surface
antigens of human lymphocytes (CD3, CD4, CD8) were
used to detect and quantitate lymphocytic infiltrates in the
myocardium (26 –29). Additionally, using antibodies
against the major histocompatibility antigens (MHC), the
expression of MHC I and II antigens was analyzed. With
these techniques, the diagnostic accuracy in the biopsies
could be increased (30) and the interobserver variability
could be minimized (31,32).
The biopsy specimens were classified as “acute myocar-
ditis” when histological sections of endomyocardial biopsies
revealed lymphocytic infiltrates in the neighborhood of
myocardial necrosis (20). “Borderline myocarditis” was di-
agnosed when lymphocytic infiltrates were present in his-
tological sections without myocyte necrosis (20) (Fig. 1A).
When the immunohistological analysis revealed pathologi-
cally increased lymphocytic infiltrates (.2.0 lymphocytes/
high power field [32]) and an increased expression of MHC
I and II antigens, the biopsy was classified as “lymphocytic
myocarditis” (Fig. 1B).
The diagnosis of “chronic myocarditis” was based on the
histological or immunohistological detection of lymphocytic
infiltrates in the myocardium in the second biopsy six
months after the initial evaluation.
Analysis of antimyosin autoantibodies. Sera of patients
with myocarditis were analyzed for the presence of
AMAAB as previously described (15). Sera were taken on
admission of the patients and immediately stored at 270°C.
Analysis of AMAAB was done in batches. Human cardiac
myosin was prepared according to Offer et al. (33) and
modified after Lompre´ et al. (34). Serum samples of patients
were incubated on enzyme-linked immunosorbent assay
(ELISA) microtiter plates with human cardiac myosin as
antigen. After removal of the serum, bound antibodies were
visualized with peroxidase-labeled goat antihuman IgG (Fa.
Sigma, St. Louis, Missouri). Extinction was read at 492 nm
in an automated ELISA reader. Specificity of the antibody
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binding to human cardiac myosin was checked by Western-
blot analysis.
Hemodynamic measurements. Left ventricular function
was measured by biplane left ventriculography in 30° right
anterior oblique and 60° left anterior oblique projections and
left ventricular pressures were recorded simultaneously by
use of a micromanometer in the left ventricle. Left ventricu-
lograms were recorded at 25 frames/s. Each left ventricular
frame was digitized by use of an electronic “digitizer”
(Numonics Corp., Montgomeryville, Pennsylvania) and
corrected for magnification by use of a reference grid. Left
ventricular volumes were calculated using the “area-length-
method” (35). Left ventricular pressures were plotted on a
Versatec Printer-Plotter in 5 ms intervals with a paper speed
of 100 mm/s. The time constant of diastolic relaxation tau
was measured according to Raff and Glantz (36). The
constant of diastolic stiffness was calculated using a mono-
exponential model with variable asymptote (37–39).
Statistical analysis. Variables were analyzed by Mann-
Whitney U test (two-sided). P values ,0.05 were consid-
ered to indicate statistical significance.
RESULTS
Histological and immunohistological analysis of endo-
myocardial biopsies in patients with chronic myocarditis.
The findings in the endomyocardial biopsies are shown in
Figure 2. At baseline, no patient showed histological evi-
dence of myocytolysis. “Borderline myocarditis” was diag-
nosed at baseline in six patients, additional immunohisto-
logical analysis demonstrated “lymphocytic myocarditis” in
all 33 patients. Evidence of interstitial fibrosis was present in
eight patients; the degree of fibrosis was not quantitated in
the small biopsy specimen.
After six months, the endomyocardial biopsy disclosed
evidence of chronic myocarditis in all patients. Histologi-
cally, no patient had “acute myocarditis”; “borderline myo-
carditis” was diagnosed in 10 patients and “lymphocytic
myocarditis” was demonstrated immunohistologically in 31
patients. Evidence of fibrosis was detected in 10 patients; in
3 of these patients, it was already present at baseline, and in
7 patients fibrosis was not detectable at baseline.
AMAAB in patients with chronic myocarditis. At
baseline, AMAAB were found in 17 (52%) patients
(Fig. 3). After six months AMAAB were still detectable in
13/17 (76%) initially antimyosin-autoantibody positive
(AMAAB[1]) patients. In 4/17 (24%) initially
AMAAB(1) patients, no AMAAB could be detected after
six months. Sixteen (48%) patients were initially
antimyosin-autoantibody negative (AMAAB[2]). After six
months, all 16 patients had remained AMAAB(2); no
patient had developed AMAAB.
Impact of AMAAB at baseline on clinical symptoms and
changes of systolic and diastolic left ventricular function.
After six months, two initially AMAAB(1) patients reported
moderate clinical improvement of symptoms (New York Heart
Association [NYHA] class), two initially AMAAB(1) pa-
Figure 1. Representative histologic and immunohistologic pictures
of biopsy specimen from patients with myocarditis. A: histology
(borderline myocarditis). B: immunohistology (lymphocytic myo-
carditis).
Figure 2. Histological and immunohistological analysis of the
endomyocardial biopsies in 33 patients with chronic myocarditis at
baseline and at follow-up (six months). Acute MC 5 acute
myocarditis (histology); bord MC 5 borderline myocarditis (his-
tology); lymph MC 5 lymphocytic myocarditis (immunohistolo-
gy); no MC 5 no myocarditis (histology or immunohistology).
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tients reported moderate deterioration of symptoms (1 NYHA
class), whereas six initially AMAAB(2) patients reported
moderate improvement of clinical symptoms (1 NYHA class)
and no initially AMAAB(2) patient reported clinical deteri-
oration. Severity of myocardial invasion by lymphocytic cells
was not different between AMAAB(1) and AMAAB(2)
patients [AMAAB(1): 2.6 6 1.3, lymphocytes/high power
field, AMAAB(2): 2.6 6 1.1 lymphocytes/high power field).
Parameters of systolic and diastolic left ventricular function at
baseline and after six months of 17 AMAAB(1) and 16
AMAAB(2) patients are shown in Table 1. After six months
left ventricular ejection fraction (EF) as well as stroke volume
(SV) and stroke volume index (SVI) had significantly improved
in AMAAB(2) patients compared with AMAAB(1) patients
(EF: p , 0.028, SV: p , 0.019, SVI: p , 0.025). The changes
of end-diastolic volume (EDV), end-diastolic volume index
(EDVI), end-systolic volume (ESV) and end-systolic volume
index (ESVI) were not different between AMAAB(1) and
AMAAB(2) patients. Preload (left ventricular end diastolic
pressure [LVEDP]) and afterload (systolic arterial pressure) of
the left ventricle were not different at baseline between
AMAAB(1) and AMAAB(2) patients and did not change
during the study in both groups. The development of the
constant of diastolic stiffness “b” was better in AMAAB(2)
patients compared with AMAAB(1) patients (p , 0.068).
The change in the time constant of diastolic relaxation “tau”
was not different between AMAAB(1) and AMAAB(2)
patients. Right atrial pressure was not different between the
study groups throughout the study.
Seventeen patients had impaired systolic left ventricular
function (EF , 50%) at baseline, 8 of these patients were
AMAAB(1), 9 patients were AMAAB(2). Severity of
myocardial invasion by lymphocytic cells was not differ-
ent between the two groups (AMAAB[1]: 2.3 6 1.4
lymphocytes/high power field, AMAAB[2]: 2.6 6 1.2
lymphocytes/high power field). Parameters of left ven-
tricular systolic and diastolic function of AMAAB(1)
and AMAAB(2) patients with impaired left ventricular
function at baseline are given in Table 2. Ejection
fraction in AMAAB(2) patients with impaired left
ventricular function had improved after six months and
slightly deteriorated in AMAAB(1) patients with im-
paired left ventricular function (p , 0.021). The differ-
ence in change of SV and SVI did not reach statistical
significance. Changes in EDV, EDVI, ESV and ESVI
were not different between AMAAB(1) and AMAAB(2)
patients. Diastolic stiffness improved significantly in
AMAAB(2) patients compared with AMAAB(1) patients
(p , 0.036). Changes in “tau” were not different between
AMAAB(1) and AMAAB(2) patients.
Impact of persistence of AMAAB at follow-up (six
months) on clinical symptoms and changes of systolic
and diastolic left ventricular function. Thirteen of 17
initially AMAAB(1) patients demonstrated persistence of
AMAAB after six months; all initially AMAAB(2) pa-
tients were still AMAAB(2) at follow-up. Two persistently
AMAAB(1) patients reported moderate clinical improve-
ment of symptoms (1 NYHA class), two persistently
AMAAB(1) patients reported moderate deterioration of
symptoms (1 NYHA class). Six persistently AMAAB(2)
Figure 3. Antimyosin autoantibodies in patients with chronic
myocarditis at baseline and at follow-up (six months). AMAAB 5
antimyosin autoantibodies.
Table 1. Systolic and Diastolic Left Ventricular Function at Baseline and After Six Months of Initially AMAAB(1) (n 5 17) and
Initially AMAAB(2) (n 5 16) Patients With Chronic Myocarditis
Baseline
Change From Baseline to
Follow-Up (6 Months)
pAMAAB(1) AMAAB(2) AMAAB(1) AMAAB(2)
Left ventricular end-diastolic pressure (mm Hg) 17.1 6 8.1 13.6 6 10.2 12.2 6 9.0 11.5 6 10.4 0.687
Ejection fraction (%) 55.1 6 22.7 47.8 6 19.9 20.1 6 9.4 18.9 6 10.1 0.028
End-diastolic volume (ml) 291 6 168 248 6 99 223 6 68 24 6 61 0.245
End-diastolic volume index (ml) 150 6 83 130 6 51 211 6 35 23 6 32 0.382
End-systolic volume (ml) 162 6 161 144 6 99 29 6 43 218 6 45 0.581
End-systolic volume index (ml) 82 6 80 76 6 52 23 6 22 210 6 24 0.465
Stroke volume (ml) 129 6 34 104 6 41 214 6 43 120 6 31 0.019
Stroke volume index (ml) 68 6 19 54 6 20 28 6 22 110 6 17 0.025
Rate constant of diastolic relaxation “tau” (ms) 85.7 6 22.4 82.5 6 16.7 11.6 6 26.8 13.6 6 25.6 0.845
Constant of diastolic stiffness “b” 29.5 6 23.1 38.2 6 39.4 17.3 6 22.6 26.1 6 10.8 0.068
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patients reported moderate improvement of clinical symp-
toms (1 NYHA class), no persistently AMAAB(2)
patient reported clinical deterioration. Severity of myocar-
dial invasion by lymphocytic cells was not different between
persistently AMAAB(1) and persistently AMAAB(2) pa-
tients (AMAAB[1]: 2.5 6 1.3 lymphocytes/high power
field, AMAAB[2]: 2.6 6 1.1 lymphocytes/high power
field). Parameters of left ventricular systolic and diastolic
function of persistently AMAAB(1) or persistently
AMAAB(2) patients are shown in Table 3. Ejection
fraction had improved significantly after six months in
persistently AMAAB(2) patients compared with per-
sistently AMAAB(1) patients (p , 0.028). The differ-
ence in change of SV and SVI did not reach statistical
significance. Changes of EDV, EDVI, ESV and ESVI
were not different between the two groups. The change in
diastolic stiffness “b” was significantly better in persistently
AMAAB(2) patients than in persistently AMAAB(1)
patients (p , 0.017), whereas the change in the time
constant of diastolic relaxation tau was not different between
the two groups. Seven persistently AMAAB(1) patients
and nine persistently AMAAB(2) patients had impaired
systolic left ventricular function (EF ,50%) at baseline.
Severity of myocardial invasion by lymphocytic cells was
not different between the two groups (AMAAB[1]:
2.2 6 1.0 lymphocytes/high power field, AMAAB[2]:
2.6 6 1.2 lymphocytes/high power field). Parameters of
left ventricular systolic and diastolic function in these patients
are given in Table 4. Ejection fraction had improved after six
months in persistently AMAAB(2) patients with impaired
left ventricular function compared with persistently
AMAAB(1) patients with impaired left ventricular function
(p , 0.042). The difference in change of SV and SVI did not
reach statistical significance. Changes in EDV, EDVI, ESV
and ESVI were not different between the study groups.
Diastolic stiffness improved significantly in AMAAB(2) pa-
tients compared with AMAAB(1) patients (p , 0.005).
Changes in “tau” were not different between the two groups.
DISCUSSION
Autoantibodies against cardiac myosin have been found in
patients with myocarditis (15) and dilated cardiomyopathy
(16). These AMAAB are directed against alpha- and
Table 2. Systolic and Diastolic Left Ventricular Function at Baseline and After Six Months of Initially AMAAB(1) (n 5 8) and
Initially AMAAB(2) (n 5 9) Patients With Chronic Myocarditis With Impaired Left Ventricular Function at Baseline (EF , 50%)
Baseline
Change From Baseline to
Follow-Up (6 Months)
pAMAAB(1) AMAAB(2) AMAAB(1) AMAAB(2)
Left ventricular end-diastolic pressure (mm Hg) 21.7 6 7.9 16.2 6 12.3 12.9 6 11.9 11.8 6 13.1 0.945
Ejection fraction (%) 33.3 6 9.6 32.4 6 10.6 22.1 6 9.3 112.2 6 11.6 0.021
End-diastolic volume (ml) 423 6 158 296 6 83 226 6 94 233 6 57 0.743
End-diastolic volume index (ml) 215 6 78 157 6 39 212 6 50 218 6 30 0.888
End-systolic volume (ml) 294 6 146 208 6 95 210 6 62 234 6 53 0.200
End-systolic volume index (ml) 148 6 71 110 6 44 23 6 32 218 6 28 0.167
Stroke volume (ml) 128 6 31 88 6 18 216 6 54 111 6 28 0.277
Stroke volume index (ml) 66 6 20 47 6 8 29 6 28 16 6 15 0.321
Rate constant of diastolic relaxation “tau” (ms) 77.6 6 20.9 81.6 6 15.8 110.2 6 29.3 19.5 6 24.9 0.888
Constant of diastolic stiffness “b” 30.5 6 24.4 38.5 6 38.5 114.6 6 28.4 29.9 6 13.0 0.036
Table 3. Systolic and Diastolic Left Ventricular Function at Baseline and After Six Months of Persistently AMAAB(1) (n 5 13)
and Persistently AMAAB(2) (n 5 16) Patients With Chronic Myocarditis
Baseline
Change From Baseline to
Follow-Up (6 Months)
pAMAAB(1) AMAAB(2) AMAAB(1) AMAAB(2)
Left ventricular end-diastolic pressure (mm Hg) 18.4 6 8.2 13.6 6 10.2 12.9 6 9.9 11.5 6 10.4 0.557
Ejection fraction (%) 52.5 6 24.8 47.8 6 19.9 20.7 6 9.5 18.9 6 10.1 0.028
End-diastolic volume (ml) 319 6 178 248 6 99 220 6 78 246 6 61 0.351
End-diastolic volume index (ml) 161 6 87 130 6 51 29 6 40 23 6 32 0.503
End-systolic volume (ml) 188 6 174 144 6 99 28 6 49 218 6 45 0.589
End-systolic volume index (ml) 93 6 86 76 6 52 23 6 25 210 6 24 0.503
Stroke volume (ml) 131 6 35 104 6 41 212 6 49 120 6 31 0.092
Stroke volume index (ml) 67 6 18 54 6 20 26 6 25 110 6 17 0.110
Rate constant of diastolic relaxation “tau” (ms) 82.6 6 24.5 82.5 6 16.7 13.9 6 28.8 13.6 6 25.5 0.983
Constant of diastolic stiffness “b” 26.1 6 22.9 38.2 6 39.4 19.9 6 21.1 26.1 6 10.8 0.017
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beta-cardiac myosin heavy chains (16). At the time of
diagnosis, these autoantibodies are not associated with
specific clinical or diagnostic features (15,40). In patients
with dilated cardiomyopathy, 52% of the patients who
showed AMAAB at baseline, became antibody negative
after one year and no initially antibody-negative patient
became antibody-positive at follow-up (18). This is in
concordance with this study where 22% of the initially
AMAAB(1) patients with myocarditis had lost their auto-
antibodies after six months and no initially antibody-
negative patient had developed AMAAB at follow-up.
AMAAB and left ventricular function. This study is the
first report that evaluates the time course of systolic and
diastolic left ventricular function in patients with myocar-
ditis and autoantibodies against cardiac antigens. In patients
with histologically or immunohistologically diagnosed myo-
carditis, the presence of AMAAB is associated with less
favorable development of systolic and diastolic left ventric-
ular function during a six month follow-up period. The
change in parameters of systolic left ventricular function
(EF, SV, SVI) were significantly better in patients without
AMAAB compared with AMAAB(1) patients. This seems
not to be due to different preload or afterload of the left
ventricle in the two study groups as left ventricular end-
diastolic pressure and systolic arterial pressure were not
different between the groups at baseline and had not
changed at follow-up.
The development of diastolic left ventricular function was
also different between AMAAB(1) and AMAAB(2) pa-
tients. The constant of diastolic stiffness “b” was higher at
follow-up in AMAAB(1) patients compared with baseline,
whereas “b” was lower compared with baseline in
AMAAB(2) patients, i.e., the left ventricle in AMAAB(1)
patients became stiffer and less compliant than it did in
AMAAB(2) patients. Left ventricular relaxation did not
change throughout the study period in either group.
The pathophysiologic mechanisms responsible for the
development of less compliant ventricles in patients with
AMAAB are not clear. Patients with myocarditis show
various degrees of interstitial fibrosis in the myocardium
(41). In patients with presumably chronic myocarditis,
massive interstitial fibrosis has been found (42). Therefore,
it could be possible that in this study AMAAB(1) patients
had developed more fibrosis in six months than
AMAAB(2) patients. However, no studies evaluating the
time course of the development of interstitial fibrosis in
patients with myocarditis are yet available. In this study,
interstitial fibrosis could not be evaluated quantitatively in
the small biopsy specimen. “Vascular turgor” (43) was not
different in the two study groups. Other possible causes for
increased chamber stiffness such as amyloidosis or myocar-
dial edema cannot be ruled out in this study; however, they
seem unlikely to be responsible for the observed changes in
left ventricular stiffness.
AMAAB and clinical course of myocarditis and dilated
cardiomyopathy. In this study, patients with chronic myo-
carditis and AMAAB reported no change in clinical symp-
toms after six months; patients without AMAAB reported
slight improvement of symptoms. Caforio et al. (18) ana-
lyzed AMAAB and the clinical course in patients with
dilated cardiomyopathy. Persistence of AMAAB was asso-
ciated with milder symptoms at presentation and stable
disease. In this study, the diagnosis of dilated cardiomyop-
athy was based only on histological analysis of the endo-
myocardial biopsy. The histological analysis alone of the
endomyocardial biopsy is known to be difficult (21,22) and
affected by many problems including high “interobserver-
variability” (23) and sampling error (24). Therefore, histo-
logical analysis alone is thought to be rather insensitive for
the diagnosis of myocarditis (26–29). This study employs
both histological and immunohistological analysis of the
endomyocardial biopsy specimen. With these techniques,
lymphocytic infiltrates could be detected in 48% of patients
presenting with the clinical picture of dilated cardiomyop-
athy, whereas histological analysis alone found myocarditis
in only 5% of patients (32). Therefore, it cannot be ruled out
Table 4. Systolic and Diastolic Left Ventricular Function at Baseline and After Six Months of Persistently AMAAB(1) (n 5 7) and
Persistently AMAAB(2) (n 5 9) Patients With Chronic Myocarditis With Impaired Left Ventricular Function at Baseline (EF , 50%)
Baseline
Change From Baseline to
Follow-Up (6 Months)
pAMAAB(1) AMAAB(2) AMAAB(1) AMAAB(2)
Left ventricular end-diastolic pressure (mm Hg) 22.7 6 8.1 16.2 6 12.3 12.7 6 13.1 11.8 6 13.1 0.937
Ejection fraction (%) 31.0 6 8.1 32.4 6 10.6 21.7 6 10.0 112.2 6 11.6 0.042
End-diastolic volume (ml) 437 6 164 296 6 83 224 6 102 233 6 57 0.681
End-diastolic volume index (ml) 217 6 83 157 6 39 211 6 53 218 6 30 0.918
End-systolic volume (ml) 313 6 147 208 6 95 210 6 67 234 6 53 0.252
End-systolic volume index (ml) 155 6 74 110 6 44 23 6 35 218 6 28 0.210
Stroke volume (ml) 124 6 31 88 6 18 213 6 58 111 6 28 0.470
Stroke volume index (ml) 62 6 17 47 6 8 27 6 30 16 6 15 0.536
Rate constant of diastolic relaxation “tau” (ms) 73.4 6 19.1 81.6 6 15.8 115.5 6 27.2 19.5 6 24.9 0.536
Constant of diastolic stiffness “b” 25.9 6 22.5 38.5 6 38.5 120.9 6 23.9 29.9 6 13.0 0.005
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that some patients in the study of Caforio et al. (18)
probably had lymphocytic myocarditis and that the patients
presented in this study may probably not represent a
homogeneous group of dilated cardiomyopathy.
Pathophysiologic relevance of AMAAB. The pathophys-
iologic significance of AMAAB in patients with myocarditis
is poorly understood. In animal studies, autoantibodies
against cardiac myosin have been demonstrated in Cox-
sackie B3 virus induced myocarditis (44,45). Immunization
of the animals with cardiac myosin results in histologic and
immunohistologic alterations similar to those seen after
Coxsackie B3 virus infection (46). These results suggest a
pathophysiologic role of AMAAB in the course of myocar-
ditis. One possible explanation could be “molecular mimic-
ry.” Schwimmbeck et al. (47) identified regions of high
homology between Coxsackie B3 virus and rabbit cardiac
myosin heavy chain. However, the AMAAB produced in
Coxsackie virus B3-induced murine myocarditis did not
cross-react with the virus (48). Another possibility is the
exposition of sequestered antigens to the immune system in
the course of myocarditis. Intracellular proteins such as
myosin are possibly exposed to the immunogenic cells, thus
perpetuating the autoimmunologic process.
This study shows that AMAAB are associated with less
favorable development of left ventricular systolic and dia-
stolic function in patients with chronic myocarditis. One
possible explanation would be that in the two study groups
different pathophysiologic mechanisms are responsible for
the development of chronic myocarditis. In AMAAB(1)
patients, chronic myocarditis may be caused by autoimmu-
nologic mechanisms, probably depending on genetic predis-
position (49), whereas in AMAAB(2) patients, other
mechanisms like persistence of viral genome in the myocar-
dium (8,50) may be responsible for the development of a
chronic disease. In this case, the AMAAB could serve as a
marker of an autoimmunologic process in the patients.
Another explanation would be that in AMAAB(2) pa-
tients, autoantibodies against other cardiac antigens (10–
14) may be responsible for the development of chronic
myocarditis and that these autoantibodies may have differ-
ent effects on cardiac function (17,19). However, it cannot
be overlooked that the AMAAB themselves may influence
cardiac function via a yet unknown mechanism. In patients
with myocarditis, in whom myocardial cell damage was
studied by antimyosin scintigraphy, the presence of
AMAAB seems to prevent the binding of the radioactively
labeled AMAAB to the myocardium (51). This suggests
that the AMAAB in these patients may bind to epitopes in
the heart and consequently may influence cardiac function.
Conclusions. This study shows that, in patients with
chronic myocarditis, the presence of autoantibodies against
cardiac myosin is associated with less favorable development
of left ventricular systolic function and diastolic stiffness in
the course of the disease.
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